Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other solid neoplasm 1

Conditions

Multiple Myeloma 1Mesothelioma, Malignant 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Safety × Clear all
NCT04525859 2025-06-24

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

Oncovir, Inc.

Phase 1 Completed
19 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02786511 2020-01-22

Longterm Follow-up of Subjects Treated With bb2121

Celgene

Completed
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡